Current and Emerging Therapies in Nonalcoholic Fatty Liver Disease

ABSTRACT

The prevalence of obesity and the metabolic syndrome (MS) is on the rise, and subsequently the hepatic manifestation of MS, nonalcoholic fatty liver disease (NAFLD), has become a common entity in clinical practice. Most patients with NAFLD face medical complications related to their underlying MS in other organ systems; however, a small but significant group of patients with the more aggressive form of fatty liver, nonalcoholic steatohepatitis (NASH), are at risk of developing cirrhosis and hepatocellular carcinoma. As patients are generally asymptomatic, often their disease goes unrecognized. This is particularly true for NASH, where liver biopsy is currently required to make the diagnosis. Once diagnosed, no one treatment has been shown to be universally efficacious and those that are of benefit are not without side effects. Effective treatment regimens directed at both decreasing insulin resistance as well as the processes leading to necroinflammation and hepatic fibrosis have been investigated and include lifestyle modification, surgical therapies, and pharmacotherapy. This review focuses on current and potential future therapies for NASH.

KEYWORDS

Fatty liver - nonalcoholic steatohepatitis (NASH) - nonalcoholic fatty liver disease (NAFLD) - metabolic syndrome - thiazolidinediones (TZDs)

REFERENCES

• 1 Zelman S. The liver in obesity.  AMA Arch Intern Med. 1952;  90 141-156
• 2 Westwater J O, Fainer D. Liver impairment in the obese.  Gastroenterology. 1958;  34 686-693
• 3 Ludwig J, Viggiano T R, McGill D B, Oh B J. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease.  Mayo Clin Proc. 1980;  55 434-438
• 4 Bugianesi E, Gentilcore E, Manini R et al.. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease.  Am J Gastroenterol. 2005;  100 1082-1090
• 5 Singh S P. Non-alcoholic fatty liver disease: the unfolding monster?.  J Gastroenterol Hepatol. 2006;  21 199-201
• 6 Marchesini G, Brizi M, Morselli-Labate A M et al.. Association of nonalcoholic fatty liver disease with insulin resistance.  Am J Med. 1999;  107 450-455
• 7 Falck-Ytter Y, Younossi Z M, Marchesini G, McCullough A J. Clinical features and natural history of nonalcoholic steatosis syndromes.  Semin Liver Dis. 2001;  21 17-26
• 8 Day C P, James O F. Steatohepatitis: a tale of two “hits”?.  Gastroenterology. 1998;  114 842-845
• 9 Harrison S A, Day C P. Benefits of lifestyle modification in NAFLD.  Gut. 2007;  56 1760-1769
• 10 Abdelmalek M F, Diehl A M. Nonalcoholic fatty liver disease as a complication of insulin resistance.  Med Clin North Am. 2007;  91 1125-1149
• 11 Bloom S R, Kuhajda F P, Laher I et al.. The obesity epidemic: pharmacological challenges.  Mol Interv. 2008;  8 82-98
• 12 Pereira M A, Kartashov A I, Ebbling C B et al.. Fast food habits, weight gain, and insulin resistance (the CARDIA study): 15-year prospective analysis.  Lancet. 2005;  365 36-42
• 13 Kechagias S, Ernersson A, Dahlqvist O et al.. Fast-food-based hyper-alimentation can induce rapid and profound elevation of serum alanine aminotransferase in healthy subjects.  Gut. 2008;  57 649-665
• 14 Bonora E, Kiechl S, Willeit J et al.. Prevalence of insulin resistance in metabolic disorders: the Bruneck study.  Diabetes. 1998;  47 1643-1649
• 15 Nielsen S J, Popkin B M. Changes in beverage intake between 1977 and 2001.  Am J Prev Med. 2004;  27 205-209
• 16 Elwood P C, Pickering J E, Fehily A M. Milk and dairy consumption, diabetes and the metabolic syndrome: the Caerphilly prospective study.  J Epidemiol Community Health. 2007;  61 695-698
• 17 Ouyang X, Cirillo P, Sautin Y et al.. Fructose consumption as a risk factor for non-alcoholic fatty liver disease.  J Hepatol. 2008;  48 993-999
• 18 Cave M, Deaciuc I, Mendez C et al.. Nonalcoholic fatty liver disease: predisposing factors and the role of nutrition.  J Nutr Biochem. 2007;  18 184-195
• 19 Hickman I J, Jonsson J R, Prins J B et al.. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life.  Gut. 2004;  53 413-419
• 20 Suzuki A, Lindor K, St Saver J et al.. Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease.  J Hepatol. 2005;  43 1060-1066
• 21 Ueno T, Sugawara H, Sujaka K et al.. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver.  J Hepatol. 1997;  27 103-107
• 22 Tock L, Prado W L, Caranti D A et al.. Nonalcoholic fatty liver disease decrease in obese adolescents after multidisciplinary therapy.  Eur J Gastroenterol Hepatol. 2006;  18 1241-1245
• 23 Harrison S A, DiBisceglie A M. Advances in the understanding and treatment of nonalcoholic fatty liver disease.  Drugs. 2003;  63 2379-2394
• 24 Lin H Z, Yang S Q, Chuckaree C, Kuhajda F, Ronnet G, Diehl A M. Metformin reverses fatty liver disease in obese, leptin-deficient mice.  Nat Med. 2000;  6 998-1003
• 25 Marchesini G, Brizi M, Bianchi G et al.. Metformin in non-alcoholic steatohepatitis.  Lancet. 2001;  358 893-894
• 26 Uygun A, Kadayifci A, Isik A T et al.. Metformin in the treatment of patients with non-alcoholic steatohepatitis.  Aliment Pharmacol Ther. 2004;  19 537-544
• 27 Nair S, Diehl A M, Wiseman M, Farr G H, Perrillo R P. Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial.  Aliment Pharmacol Ther. 2004;  20 23-28
• 28 Caldwell S H, Hespenheide E E, Redick J A et al.. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis.  Am J Gastroenterol. 2001;  96 519-525
• 29 Neuschwander-Tetri B A, Brunt E M, Wehmeier K R, Oliver D, Bacon B R. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone.  Hepatology. 2003;  38(4) 1008-1017
• 30 Belfort R, Harrison S A, Brown K et al.. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.  N Engl J Med. 2006;  355 2297-2307
• 31 Aithal G P, Aithal G P, Thomas J A et al.. A randomized double blind, placebo controlled trial of one year of pioglitazone in non-diabetic subjects with non-alcoholic steatohepatitis.  Hepatology. 2007;  46(suppl 1) 295A
• 32 Thomas J A, Kaye P et al.. A randomized double blind, placebo controlled trial of one year of pioglitazone in non-diabetic subjects with non-alcoholic steatohepatitis.  Hepatology. 2007;  46 295A
• 33 Ratziu V, Giral P, Jacqueminet S et al.. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized, placebo-controlled FLIRT trial.  Gastroenterology. 2008;  135 100-110
• 34 Nissen S E, Wolski K. The effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular issues.  N Engl J Med. 2007;  356 2457-2471
• 35 Murphy C E, Rodgers P T. Effects of thiazolidinediones on bone loss and fracture.  Ann Pharmacother. 2007;  41 2014-2018
• 36 Amori R E, Lau J, Pittas A G. Efficacy and safety of incretin therapy in type 2 diabetes mellitus.  JAMA. 2007;  298 194-206
• 37 Ding X, Saxena N K, Lin S et al.. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice.  Hepatology. 2006;  43 173-181
• 38 Tushuizen M E, Brunck M C, Pouwels P J et al.. Incretin mimetics as a novel therapeutic option for hepatic steatosis.  Liver Int. 2006;  26 1015-1017
• 39 Baggio L L, Huang Q, Cao X, Drucker D J. An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis.  Gastroenterology. 2008;  134 1137-1147
• 40 Ekstedt M, Franzen L E, Mathiesen U L et al.. Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study.  J Hepatol. 2007;  47 135-141
• 41 Bhardwaj S S, Chalasani N. Lipid-lowering agents that cause drug-induced hepatotoxicity.  Clin Liver Dis. 2007;  11 597-613
• 42 Cohen D E, Anania F A, Chalasani N. National Lipid Association Statin Safety Task Force Liver Expert Panel . An assessment of statin safety by hepatologists.  Am J Cardiol. 2006;  97 77C-81C
• 43 Lewis J H, Mortensen M E, Zweig S et al.. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial.  Hepatology. 2007;  46 1453-1463
• 44 Vuppalanchi R, Chalasani N. Statins for hyperlipidemia in patients with chronic liver disease: are they safe?.  Clin Gastroenterol Hepatol. 2006;  4 838-839
• 45 Chalasani N, Aljadhey H, Kesterson J, Murray M D, Hall S D. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity.  Gastroenterology. 2004;  126 1287-1292
• 46 Rallidis L S, Drakoulis C K, Parasi A S. Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study.  Atherosclerosis. 2004;  174 193-196
• 47 Lindor K D, Kowdley K V, Heathcote E J et al.. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial.  Hepatology. 2004;  39 770-778
• 48 Itoh S, Kanazuka A, Akimoto T. Combined treatment with ursodeoxycholic acid and pioglitazone in a patient with NASH associated with type 2 diabetes and psoriasis.  Dig Dis Sci. 2003;  48 2182-2186
• 49 Laurin J, Lindor K D, Crippin J S et al.. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study.  Hepatology. 1996;  23 1464-1467
• 50 Bauditz J, Schmidt H H, Dippe P, Lochs H, Pirlich M. Non-alcohol induced steatohepatitis in non-obese patients: treatment with ursodeoxycholic acid.  Am J Gastroenterol. 2004;  99 959-960
• 51 Vajro P, Mandato C, Franzese A et al.. Vitamin E treatment in pediatric obesity-related liver disease: a randomized study.  J Pediatr Gastroenterol Nutr. 2004;  38 48-55
• 52 Lavine J E. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study.  J Pediatr. 2000;  136 734-738
• 53 Kugelmas M, Hill D B, Vivian B, Marsano L, McClain C J. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E.  Hepatology. 2003;  38 413-419
• 54 Harrison S A, Torgerson S, Hayashi P, Ward J, Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis.  Am J Gastroenterol. 2003;  98 2485-2490
• 55 Barak A J, Beckenhauer H C, Junnila M, Tuma D J. Dietary betaine promotes generation of hepatic S-adenosylmethionine and protects the liver from ethanol-induced fatty infiltration.  Alcohol Clin Exp Res. 1993;  17 552-555
• 56 Abdelmalek M F, Angulo P, Jorgensen R A, Sylvestre P B, Lindor K D. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study.  Am J Gastroenterol. 2001;  96 2711-2717
• 57 Patrick L. Nonalcoholic fatty liver disease: relationship to insulin sensitivity and oxidative stress. Treatment approaches using vitamin E, magnesium, and betaine.  Altern Med Rev. 2002;  7 276-291
• 58 Harrison S A, Fincke C, Helinski D, Torgerson S, Hayashi P. A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients.  Aliment Pharmacol Ther. 2004;  20 623-628
• 59 Zelber-Sagi S, Kessler A, Brazowsky E et al.. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease.  Clin Gastroenterol Hepatol. 2006;  4 639-644
• 60 Harrison S A, Ramrakhiani S, Brunt E M, Anbari M A, Cortese C, Bacon B R. Orlistat in the treatment of NASH: a case series.  Am J Gastroenterol. 2003;  98 926-930
• 61 Banasch M, Goetze O, Schmidt W E, Meier J J. Rimonabant as a novel therapeutic option for nonalcoholic steatohepatitis.  Liver Int. 2007;  27 1152-1155
• 62 Woods S C. Role of the endocannabinoid system in regulating cardiovascular and metabolic risk factors.  Am J Med. 2007;  120 S19-S25
• 63 Van Gaal L F, Rissanen A M, Scheen A J, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonibant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.  Lancet. 2005;  365 1389-1397
• 64 Pi-Sunyer F X, Aronne L J, Heshmati H M, Devin J, Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiovascular risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial.  JAMA. 2006;  295 761-775
• 65 Despres J P, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.  N Engl J Med. 2005;  353 2121-2134
• 66 Scheen A J, Finer N, Hollander P, Jensen M D, Van Gaal L F. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomized controlled study.  Lancet. 2006;  368 1660-1672
• 67 Kral J G, Thung S N, Biron S et al.. Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis.  Surgery. 2004;  135 48-58
• 68 Dixon J B, Bhathal P S, Hughes N R, O'Brien P E. Nonalcoholic fatty liver disease: improvement in liver histologic analysis with weight loss.  Hepatology. 2004;  39 1647-1654
• 69 Mathurin P, Gonzalez F, Kerdraon O et al.. The evolution of severe steatosis after bariatric surgery is related to insulin resistance.  Gastroenterology. 2006;  130 1617-1624
• 70 Furuya C K, de Oliveira C PMS, de Mello E S et al.. Effects of bariatric surgery on nonalcoholic fatty liver disease: preliminary findings after 2 years.  J Gastroenterol Hepatol. 2007;  22 510-514
• 71 Mattar S G, Velcu L M, Rabinovitz M et al.. Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome.  Ann Surg. 2005;  242 610-620
• 72 Barker K B, Palekar N A, Bowers S P et al.. Non-alcoholic steatohepatitis: effect of Roux-en-Y gastric bypass surgery.  Am J Gastroenterol. 2006;  101 368-373
• 73 de Almeida S R, Rocha P RS, Sanches M D et al.. Roux-en-Y gastric bypass improves the nonalcoholic steatohepatitis (NASH) of morbid obesity.  Obes Surg. 2006;  16 270-278
• 74 Clark J M, Alkhuraishi A RA, Solga S et al.. Roux-en-Y gastric bypass improves liver histology in patients with non-alcoholic fatty liver disease.  Obes Res. 2005;  13 1180-1186
• 75 Mottin C C, Moretto M, Padoin A V et al.. Histological behavior of hepatic steatosis in morbidly obese patients after weight loss induced by bariatric surgery.  Obes Surg. 2005;  15 788-793
• 76 Liu X, Lazenby A J, Clements R H, Jhala N, Abrams G A. Resolution of nonalcoholic steatohepatitis after gastric bypass surgery.  Obes Surg. 2007;  17 486-492
• 77 Csendes A, Smok G, Burgos A M. Histologic findings in the liver before and after gastric bypass.  Obes Surg. 2006;  16 607-611
• 78 Promrat K, Lutchman G, Uwaifo G I et al.. A pilot study of pioglitazone for the treatment of nonalcoholic steatohepatitis.  Hepatology. 2004;  39 188-196
• 79 Sanyal A J, Mofrad P S, Contos M J et al.. A pilot study of vitamin E versus vitamin E and pioglitazaone in the treatment of nonalcoholic steatohepatitis.  Clin Gastroenterol Hepatol. 2004;  2 1107-1115
• 80 Lutchman G, Modi A, Kleiner D E et al.. The effect of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis.  Hepatology. 2007;  46 424-429
• 81 Idilman R, Mizrak D, Corapcioglu D et al.. Insulin sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis.  Aliment Pharmacol Ther. 2008;  28 200-208
• 82 Luyckx F H, Desaive C, Thiry A et al.. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty.  Int J Obes Relat Metab Disord. 1998;  22 222-226
• 83 Verna E C, Berk P D. Role of fatty acids in the pathogenesis of obesity and fatty liver: impact of bariatric surgery.  Semin Liver Dis. 2008;  28 407-426